<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: In type 2 <z:hpo ids='HP_0000819'>diabetes mellitus</z:hpo> (T2DM), <z:mp ids='MP_0003674'>oxidative stress</z:mp> gives rise to <z:e sem="disease" ids="C0856169" disease_type="Disease or Syndrome" abbrv="">endothelial dysfunction</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain><z:chebi fb="0" ids="16990">Bilirubin</z:chebi>, a powerful endogenous <z:chebi fb="11" ids="22586">antioxidant</z:chebi>, significantly attenuates <z:e sem="disease" ids="C0856169" disease_type="Disease or Syndrome" abbrv="">endothelial dysfunction</z:e> in preclinical experiments </plain></SENT>
<SENT sid="2" pm="."><plain>The <z:e sem="disease" ids="C0017551" disease_type="Disease or Syndrome" abbrv="">Gilbert syndrome</z:e> is accompanied by a mild and lifelong <z:hpo ids='HP_0002904'>hyperbilirubinemia</z:hpo> and associated with only one third of the usual cardiovascular mortality risk </plain></SENT>
<SENT sid="3" pm="."><plain>The <z:hpo ids='HP_0002904'>hyperbilirubinemia</z:hpo> caused by <z:chebi fb="0" ids="37924">atazanavir</z:chebi> treatment closely resembles the <z:e sem="disease" ids="C0017551" disease_type="Disease or Syndrome" abbrv="">Gilbert syndrome</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>We thus hypothesized that treatment with <z:chebi fb="0" ids="37924">atazanavir</z:chebi> would ameliorate <z:mp ids='MP_0003674'>oxidative stress</z:mp> and <z:mp ids='MP_0001863'>vascular inflammation</z:mp> and improve endothelial function in T2DM </plain></SENT>
<SENT sid="5" pm="."><plain>METHODS AND RESULTS: In a double-blind, placebo-controlled crossover design, we induced a moderate <z:hpo ids='HP_0002904'>hyperbilirubinemia</z:hpo> by a 3-day <z:chebi fb="0" ids="37924">atazanavir</z:chebi> treatment in 16 subjects experiencing T2DM </plain></SENT>
<SENT sid="6" pm="."><plain>On the fourth day, endothelial function was assessed by venous occlusion plethysmography </plain></SENT>
<SENT sid="7" pm="."><plain>Endothelium-dependent and endothelium-independent vasodilation were assessed by intraarterial infusion of <z:chebi fb="9" ids="15355">acetylcholine</z:chebi> and <z:chebi fb="0" ids="28787">nitroglycerin</z:chebi>, respectively </plain></SENT>
<SENT sid="8" pm="."><plain><z:chebi fb="0" ids="37924">Atazanavir</z:chebi> treatment induced an increase in average <z:chebi fb="0" ids="16990">bilirubin</z:chebi> levels from 7 μmol/L (0.4 mg/dL) to 64 μmol/L (3.8 mg/dL) </plain></SENT>
<SENT sid="9" pm="."><plain>A significant improvement in plasma <z:chebi fb="11" ids="22586">antioxidant</z:chebi> capacity (P&lt;0.001) and endothelium-dependent vasodilation (P=0.036) and a decrease in plasma <z:e sem="disease" ids="C0042974" disease_type="Disease or Syndrome" abbrv="">von Willebrand</z:e> factor (P=0.052) were observed </plain></SENT>
<SENT sid="10" pm="."><plain>CONCLUSIONS: Experimental <z:hpo ids='HP_0002904'>hyperbilirubinemia</z:hpo> is associated with a significant improvement of endothelial function in T2DM </plain></SENT>
</text></document>